VIVALDI: Valdoxan improves depressive symptoms and normalises circadian rhythms - an observational prospective study.
Phase of Trial: Phase IV
Latest Information Update: 05 Sep 2017
At a glance
- Drugs Agomelatine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms VIVALDI
- Sponsors Servier
- 30 Oct 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 27 May 2009 New trial record